BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260519
DTEND;VALUE=DATE:20260522
DTSTAMP:20260515T044457
CREATED:20260217T121251Z
LAST-MODIFIED:20260217T124142Z
UID:42916-1779148800-1779407999@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences West
DESCRIPTION:Returning for its 8th year\, LEAP HR: Life Sciences West brings together 100+ senior HR leaders from scaling and stabilizing biotech organizations to navigate volatility and drive measurable business impact. \nAcross three days of high-impact sessions\, including case studies\, benchmarking\, roundtables\, and structured networking\, attendees will gain practical strategies to build lean HR functions\, retain top talent\, and respond to immigration shifts and political change. \nThis is the only forum dedicated to the unique people challenges facing West Coast life sciences organizations. Join us this May to connect\, benchmark\, and lead with confidence in a rapidly evolving market. \nTo know more visit: https://ter.li/caoti5
URL:http://www.pharmajournalist.com/event/leap-hr-life-sciences-west-2026/
LOCATION:Wyndham San Diego Bayside\, 1355 N Harbor Dr\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260519
DTEND;VALUE=DATE:20260522
DTSTAMP:20260515T044457
CREATED:20260211T085701Z
LAST-MODIFIED:20260211T085701Z
UID:42865-1779148800-1779407999@www.pharmajournalist.com
SUMMARY:4th Nasal Formulation & Delivery Summit
DESCRIPTION:Biopharma investment into the formulation\, delivery\, and commercialization of intranasal therapies is at an all-time high\, and there has never been such an opportunistic time to pursue nasal delivery. Alongside the market projection for intranasal therapies being forecasted to reach $21.2 billion by 2032\, 2025 breakthroughs included Atzumi being approved for migraine treatment\, and Eli Lilly’s Baqsimi now being applied to severe Hypoglycemia. The clock is ticking for biopharma to master their formulations first time for systemic and CNS targeting\, streamline preclinical and clinical trial success\, and achieve regulatory approval to drive products to market. \nIn response to this recent momentum\, the 4th Nasal Formulation & Delivery Summit is uniting 70+ biopharma professionals across C-levels\, Formulation\, Intranasal\, and roduct Development to overcome drug and device combination challenges\, perfect preclinical translation\, and alter formulations\, to achieve commercial viability for intranasal products. This is the only forum specifically dedicated to industry-focused intranasal formulation\, targeting both systemic and CNS delivery. We will combine a hyper-relevant technical focus with a commercial angle to help see your products through concept to clinic. \nIn uniting large pharma\, expanding mid-sized biotech\, and startup innovators\, you will achieve technical excellence for your formulation and delivery that will future-proof commercialization\, and meet potential partners who will co-develop your intranasal therapies. Adopt groundbreaking insights on pre-clinical and clinical intranasal study data for different delivery methods to obtain practical takeaways that will transform the trajectory of your intranasal success. Join biopharma in igniting a new era of innovation where intranasal delivery holds the power to unparalleled medical benefits. \nTo know more visit: https://ter.li/eqlf0s
URL:http://www.pharmajournalist.com/event/4th-nasal-formulation-delivery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260518
DTEND;VALUE=DATE:20260521
DTSTAMP:20260515T044457
CREATED:20260128T093131Z
LAST-MODIFIED:20260128T093339Z
UID:42798-1779062400-1779321599@www.pharmajournalist.com
SUMMARY:7th TCR-Based Therapies Summit
DESCRIPTION:New assets have entered clinic\, whilst dozens more have been disclosed\, and recent investments such as\, T-Therapeutics’ $91M Series A extension to advance their bispecific towards the clinic and Anocca’s SEK 440M raise\, pinpoint how funding and portfolio decisions have the power to define the trajectory of the TCR field. \nIt is in this context that the 7th TCR-Based Therapies Summit returns to unite fellow biopharma experts in address shared challenges and to bridge the gap between promising clinical data and long-term\, commercially viable TCR-based approaches. \nAcross three focused days\, enter into open discussions\, benchmark with peers\, participate in practical problem-solving and hear new data in presentations led by Immunocore\, Enara Bio\, Regeneron\, Eureka Therapeutics\, T-Cypher Bio\, Zelluna Immunotherapy\, and Aethon Therapeutics. \nJoin us in empowering the community to shape a more durable\, scalable\, and commercially robust future for TCR-based therapies. \nTo know more visit: https://ter.li/uhpzx3
URL:http://www.pharmajournalist.com/event/7th-tcr-based-therapies-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260512
DTEND;VALUE=DATE:20260515
DTSTAMP:20260515T044457
CREATED:20260217T122509Z
LAST-MODIFIED:20260217T122509Z
UID:42924-1778544000-1778803199@www.pharmajournalist.com
SUMMARY:Investigative & Preclinical Toxicology Summit 2026
DESCRIPTION:Optimize Model Selection\, Accelerate Timelines\, Improve Predictivity of Toxicity \nDates: May 12-14 | Location: Boston\, MA \nWhy Attend \nWith nearly 90% of drug candidates failing in the clinic and one-third of those failures driven by safety preclinical toxicology has reached a critical inflection point. Traditional models are no longer sufficient to predict human risk\, leading to costly late-stage attrition and stalled pipelines. \nThe 2026 summit marks a new era for toxicology. Following the FDA’s 2025 roadmap to reduce reliance on animal testing\, adoption of New Approach Methodologies (NAMs)\, including in vitro\, microphysiological\, and computational models\, is accelerating. CROs and technology developers are releasing innovative platforms\, but challenges remain around predictivity\, validation standards\, and regulatory alignment. \nWhat You’ll Learn \nThis industry-led forum is the only meeting dedicated to benchmarking what truly works in predictive toxicology. Key focus areas include: \n\nEvaluating in vivo\, in vitro\, and in silico strategies\nSharing real IND case studies\nDefining fit-for-purpose model selection across modalities\nAdvancing NAM adoption while ensuring regulatory compliance\n\nWho Should Attend \nIf you are responsible for: \n\nDe-risking first-in-human decisions\nImplementing innovative toxicology strategies\nImproving safety translation from preclinical to clinic\n\n…this summit is your essential forum to separate innovation from hype and build strategies that stand up both clinically and regulatorily. \n📥 Download the Event Guide to explore the full agenda\, speakers\, and registration details: \nOrganiser Name: Hanson Wade\nContact: Nisha Poyser-Reid\ninfo@hansonwade.com\n(+1) 617 455 4188
URL:http://www.pharmajournalist.com/event/investigative-preclinical-toxicology-summit-2026/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson  Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260505
DTEND;VALUE=DATE:20260508
DTSTAMP:20260515T044457
CREATED:20260223T092942Z
LAST-MODIFIED:20260223T092942Z
UID:42967-1777939200-1778198399@www.pharmajournalist.com
SUMMARY:3rd Measuring Patient Engagement Summit
DESCRIPTION:Patient engagement has shifted from a “nice to have” to a strategic necessity. \nWith regulators expecting defensible evidence\, executives demanding clear ROI\, and funding under tighter scrutiny\, every engagement initiative must show measurable value. Yet many organizations still struggle to demonstrate the true impact of their work. \nThe 3rd Measuring Patient Engagement Summit is the only event dedicated entirely to transforming patient engagement into credible\, quantifiable outcomes. Over three days\, more than 70 senior leaders from pharma\, biotech\, and patient advocacy will come together to share frameworks\, tools\, and real-world approaches that prove how patient insights drive results across development\, access\, and commercialization. \nThrough interactive workshops\, case studies\, and collaborative sessions\, attendees will: \n\nShift from anecdotal reporting to robust\, outcome-based evidence\nBenchmark strategies\, co-develop frameworks\, and measure impact across multi-year programs\nTranslate engagement activities into meaningful influence for regulators\, executives\, and patient communities\nWalk away with peer-tested methods\, practical tools\, and actionable insights to elevate engagement from activity to strategic value\n\nMeasuring activity isn’t enough anymore – demonstrating impact is what moves the industry forward. \nThis summit offers a unique non-competitive environment where you can benchmark your approaches\, collaborate directly with peers\, and gain practical tools to clearly demonstrate the value of patient engagement. For teams facing tighter budgets\, heightened scrutiny\, and rising expectations from stakeholders\, it’s the essential gathering to shift from anecdotal stories to evidence-backed impact\, and to elevate patient‑centric initiatives into strategic\, measurable drivers of organizational success. \nTo know more visit: https://ter.li/8hkio4
URL:http://www.pharmajournalist.com/event/3rd-measuring-patient-engagement-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260428
DTEND;VALUE=DATE:20260501
DTSTAMP:20260515T044457
CREATED:20260227T124527Z
LAST-MODIFIED:20260227T124643Z
UID:43045-1777334400-1777593599@www.pharmajournalist.com
SUMMARY:5th GPCRs-Targeted Drug Discovery Summit
DESCRIPTION:The GPCR field is experiencing a renaissance\, driven by renewed investment\, clinical progress\, and next-generation technologies unlocking hundreds of previously untargeted receptors. Furthermore\, we’ve recently seen Takeda and Iambic Therapeutics’ $1.7bn partnership to advance AI-driven small molecule programs\, and Kainova Therapeutics securing $32m CAD to accelerate immuno-oncology and inflammation therapies\, momentum in the GPCR space continues to build. The race is on to validate new GPCRs\, understand dynamic activation mechanisms\, and develop assays that better predict therapeutic efficacy and guide smarter candidate selection. \nReturning as the only industry-led meeting dedicated to GPCR drug discovery\, the 5th GPCR-Targeted Drug Discovery Summit features a jam-packed agenda with: \n\n12+ companies unveiling never seen before data\n12+ C-Level speakers\n9+ presentations on non-small molecule GPCR-targeting drug discovery\n\nThis is the place to learn about the latest targets\, tools\, and therapeutic strategies. Join 80+ GPCR-focused leaders across biopharma to share insights\, build collaborations\, and accelerate next-generation therapeutics from discovery to clinic. \nTo know more visit: https://ter.li/etb3m3
URL:http://www.pharmajournalist.com/event/5th-gpcrs-targeted-drug-discovery-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260428
DTEND;VALUE=DATE:20260430
DTSTAMP:20260515T044457
CREATED:20260220T105915Z
LAST-MODIFIED:20260220T105915Z
UID:42939-1777334400-1777507199@www.pharmajournalist.com
SUMMARY:2nd Neuroscience Innovation Partnering & Licensing Summit
DESCRIPTION:Returning for its second year and building on the momentum of an inaugural edition that drew 100+ senior attendees\, the 2nd Neuroscience Innovation Partnering & Licensing Summit is engineered to facilitate multiple high-impact\, in-person meetings without the distractions of a broader\, less-focused setting. Deliberately timed as an exclusive touchpoint for neuroscience business leaders to reconnect between JPM and BIO through a dedicated one-to-one partnering system\, bespoke matchmaking\, and 100% alignment in research interests. Those attending will receive a significant competitive advantage by hearing insights on aligning data packages with expectations and by nurturing relationships with key contacts in a more exclusive setting. \nWho Attends This Differentiated Business Development Initiative? \nGlobal Pharma: Heads of Business Development\, Search & Evaluation\, and Asset Scouting for Neuroscience – comparing pipelines and enabling technologies to fuel future innovation.\nInnovative Biotech: C-level executives and BD leaders across neurodegeneration\, psychiatry\, neuro-oncology\, and pain – seeking feedback\, validation\, and strategic partnerships with pharma and investors.\nInvestors & Venture Capital: Leaders focused on neuroscience investments with a higher risk appetite – looking for insights into pharma strategy and access to breakthrough opportunities. \nWith Novartis\, Roche\, Biogen\, and AbbVie all signing deals in the last 6 months alone\, now is the time to understand how to align with pharma’s interests\, to capitalize on activity and appetite for best or first-in-class neuroscience assets. \nLearn more: https://ter.li/o2406m
URL:http://www.pharmajournalist.com/event/2nd-neuroscience-innovation-partnering-licensing-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260428
DTEND;VALUE=DATE:20260501
DTSTAMP:20260515T044457
CREATED:20260122T133529Z
LAST-MODIFIED:20260122T133529Z
UID:42745-1777334400-1777593599@www.pharmajournalist.com
SUMMARY:3rd Peptide-Based Therapeutics Summit 2026
DESCRIPTION:Peptide therapies are rapidly becoming a disruptive modality\, led by Merck’s oral PCSK9 inhibitor and Johnson & Johnson’s IL23R\, with the hope to develop best-in-class drugs with improved chemistry\, formulation and clinical efficacy. \nTo shine a light on the progress of this field\, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and towards life-saving treatments. \nGathering industry leaders including Parabilis Medicines\, Circle Pharma\, Abbvie\, Merck\, Chugai Pharmaceuticals and many more\, this is your premium forum to explore: \n\nNovel computational tools\nOptimize analytical assays\nFormulating cell-specific delivery methods\nDMPK translatability towards clinical success of peptide therapies\n\nWith the likes of Alnylam\, Pfizer\, MIT\, Rapafusyn Pharma\, a stealth start-up and more already booked on to join\, be part of 100+ stakeholders from CEOs to Scientists in disciplines ranging from peptide drug discovery R&D\, medicinal chemistry\, pharmacology and formulation to accelerate this goldilocks modality from concept to commercialization. \nFor more information\, click here.
URL:http://www.pharmajournalist.com/event/3rd-peptide-based-therapeutics-summit-2026/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260428
DTEND;VALUE=DATE:20260501
DTSTAMP:20260515T044457
CREATED:20260107T093116Z
LAST-MODIFIED:20260107T093116Z
UID:42669-1777334400-1777593599@www.pharmajournalist.com
SUMMARY:5th ADC Analytical Development Summit
DESCRIPTION:The 5th ADC Analytical Development Summit is the industry’s only dedicated technical forum focused exclusively on solving the analytical challenges unique to antibody–drug conjugate (ADC) development. Designed for analytical\, bioanalytical\, and CMC leaders\, the summit brings together senior experts from across pharma and biotech to advance analytical rigor\, deepen product understanding\, and enable regulatory-ready ADC submissions as modalities grow increasingly complex. \nWhy Attend \n\nAcross three content-packed days\, attendees will gain practical insights to:\nOptimize physicochemical\, potency\, and impurity analytical methods\nDecode ADC heterogeneity and move beyond average DAR measurements\nDevelop biologically relevant bioassays for next-generation ADCs\nNavigate evolving regulatory expectations and strengthen CMC strategies\nStreamline analytical method transfer to QC and CDMOs\n\nWith actionable case studies and real-world lessons\, you’ll stay ahead as bispecifics\, dual payloads\, and novel conjugate formats progress through development pipelines. \nProgram Highlights \n\n22+ expert speakers from leading biopharma and biotech companies\n3 in-depth workshops on advanced ADC analytical strategies\n4+ panel discussions addressing current technical challenges\n12+ hours of structured networking with 80+ senior analytical scientists\n\nFeatured Speakers Include \nFrancis Poulin (Takeda)\, Melvin Flores (Sutro Biopharma)\, John Valliere-Douglas (Pfizer)\, Adrienne Wildt (AbbVie)\, Susan Clardy (Pyxis Oncology)\, and Stacey Cummins-Bitz (Eli Lilly)\, alongside experts from AstraZeneca\, Merck\, BMS\, Johnson & Johnson\, and more. \nDownload the full Event Guide to explore the complete agenda\, workshops\, and speaker faculty: https://ter.li/opm2ur
URL:http://www.pharmajournalist.com/event/5th-adc-analytical-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260427
DTEND;VALUE=DATE:20260430
DTSTAMP:20260515T044457
CREATED:20260122T134109Z
LAST-MODIFIED:20260122T134334Z
UID:42750-1777248000-1777507199@www.pharmajournalist.com
SUMMARY:PFS & Injectable Drug Devices East Coast
DESCRIPTION:As part of SAE’s leading PFS Series\, the 2026 conference will once again bring together top experts\, industry leaders\, and innovators for a three-days of key insights and networking. The conference will feature a comprehensive pre-conference focus day dedicated to advancements in device design\, followed by a dynamic two-day main conference featuring keynote plenaries\, interactive panel discussions\, and specialized topic streams covering the most pressing industry challenges and breakthrough solutions. \nFor more information\, click here.
URL:http://www.pharmajournalist.com/event/pfs-injectable-drug-devices-east-coast/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="SAE Media Group":MAILTO:neill.howard@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260420
DTEND;VALUE=DATE:20260422
DTSTAMP:20260515T044457
CREATED:20260106T122120Z
LAST-MODIFIED:20260114T145543Z
UID:42646-1776643200-1776815999@www.pharmajournalist.com
SUMMARY:SmartLab Exchange USA
DESCRIPTION:The SmartLab Exchange USA is an exclusive\, invitation-only event designed for senior laboratory\, R&D\, and digital transformation leaders across pharma\, biotech\, chemicals\, FMCG\, and food & beverage. This two-day forum brings together more than 60 decision-makers to tackle one of the industry’s most pressing challenges: how to make lab digitalization work in practice. \nEvery lab is on a different point in its digital journey – whether upgrading legacy systems\, implementing robotics\, or leveraging generative AI to streamline workflows. But the obstacles are universal: harmonizing data\, scaling automation\, and driving adoption across teams. The SmartLab Exchange USA focuses on practical strategies to overcome these hurdles and accelerate transformation. \nWhat to Expect: \n\nInteractive Roundtables: Collaborate with peers to solve common challenges.\nOne-to-One Meetings: Connect with curated solution providers offering tailored answers to your priorities.\nCase Studies & Keynotes: Learn from industry leaders who have successfully implemented digitalization and automation.\n\nUnlike traditional conferences\, the SmartLab Exchange USA offers a highly personalized experience – no crowded exhibition halls\, just focused discussions and strategic networking. This is your opportunity to benchmark your approach\, discover innovative solutions\, and build partnerships that will shape the future of your lab. \nWho Should Attend:\nSenior professionals in R&D\, QA/QC\, IT\, and digital transformation roles who are responsible for driving innovation and operational excellence. \nSpaces are strictly limited. Secure your invitation today and join us in Philadelphia for two days of strategic collaboration and innovation.
URL:http://www.pharmajournalist.com/event/smartlab-exchange-usa-2026/
LOCATION:The Logan Philadelphia\, One Logan Square\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="IQPC Exchange":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260414
DTEND;VALUE=DATE:20260417
DTSTAMP:20260515T044457
CREATED:20251125T111346Z
LAST-MODIFIED:20251125T111346Z
UID:42493-1776124800-1776383999@www.pharmajournalist.com
SUMMARY:3rd Annual GLP-1 Based Therapeutics Summit
DESCRIPTION:Welcome to the 3rd GLP-1 Based Therapeutics Summit – the essential industry forum dedicated to solving the critical challenges of GLP-1 combinations\, mastering tolerability\, drug delivery\, and seizing the multi-billion dollar opportunity in non-obesity indications. \nDriven by unprecedented clinical success\, this revolutionary drug class has created multi-billion dollar franchises\, but the market is now reaching a critical juncture where differentiation is everything. The pressure is on to move beyond monotherapy and unlock new levels of efficacy in areas like neuroscience and cardiorenal protection\, promising unparalleled potential to conquer widespread chronic diseases. \nThe 3rd GLP-1 Based Therapeutics Summit stands as the global forum for experts dedicated to accelerating this vital progress. This year\, we’re diving deep into the game-changing potential of multi-agonist combinations\, next-generation tolerability\, and strategic commercial planning. \nHear from the titans of the pharmaceutical industry\, including Eli Lilly\, AstraZeneca\, Merck\, and Takeda\, as well as innovative biotechs and financial institutions who will share their groundbreaking research and strategies for developing best-in-class treatments that transform patient lives. \nView the full event guide: https://ter.li/p453jn
URL:http://www.pharmajournalist.com/event/3rd-annual-glp-1-based-therapeutics-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260406
DTEND;VALUE=DATE:20260409
DTSTAMP:20260515T044457
CREATED:20251119T144046Z
LAST-MODIFIED:20251119T144046Z
UID:42432-1775433600-1775692799@www.pharmajournalist.com
SUMMARY:5th LNP Formulation & Process Development Summit
DESCRIPTION:Returning to Boston in April 2026\, the 5th LNP Formulation & Process Development Summit is the only industry-led meeting covering end-to-end LNP development. This Summit will be providing the latest scientific content to advance your LNP development for a variety of payloads and therapeutic applications\, from mRNA vaccines to next-generation cell and gene therapies. \nThe 2026 program will dive into 3 parallel tracks\, including: Analytical Development & Characterization\, Formulation & Delivery and Process Development & Manufacturing. This is your opportunity to divide and conquer\, where you can send different members across your team amongst 250+ LNP innovators\, to ensure you gain a comprehensive understanding of the entire LNP development pipeline. From early formulation through to commercial-scale production\, you can return to your company equipped with the insights needed to accelerate your LNP-mediated medicines. \nLearn more in the official event guide here: https://ter.li/y6ipkw \nCurated in collaboration with our Scientific Advisory Board\, Annette Bak (AstraZeneca)\, Luis Brito (Beam Therapeutics)\, and Ching Kim Tye (Sanofi)\, this premier forum is designed to deliver LNP-specific networking and knowledge sharing. Our unmissable agenda highlights include: \n\nAttracting Investment & Acquisition Opportunities with Capstan Therapeutics\, GV and Chiesi Global Rare Diseases\nAchieving Extrahepatic Targeting with LNPs with Alnylam\, Servier and Novartis\nLNPs for Cell & Gene Therapy Delivery with Yoltech Therapeutics\, Innorna and Corner Therapeutics\nInteractive LNP-Focused Workshop Day with Novo Nordisk\, GSK and Editas Medicines\nGain a Refresher on LNP Core Principles with Land Therapeutics\, Beam Therapeutics and Arbor Biotechnology\nFormulating Thermostable LNPs with Eli Lilly & Co and AstraZeneca\n\nKeen to find out more? Access our event overview on the LNP website here: https://ter.li/y6ipkw
URL:http://www.pharmajournalist.com/event/5th-lnp-formulation-process-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260324
DTEND;VALUE=DATE:20260327
DTSTAMP:20260515T044457
CREATED:20260123T104451Z
LAST-MODIFIED:20260123T110056Z
UID:42781-1774310400-1774569599@www.pharmajournalist.com
SUMMARY:9th Gene Therapy Development Summit
DESCRIPTION:Gene therapy is entering a defining new chapter. After a period of challenge and recalibration\, the field is regaining momentum\, driven by resilient teams who remain committed to transforming patients’ lives. With renewed confidence\, fresh investment\, and major acquisitions signalling a return to growth\, the industry is refocusing on overcoming the critical barriers of safety\, efficacy\, scalability\, and commercial viability. \nThe 9th Gene Therapy Development Summit returns to Boston as the premier meeting point for the global gene therapy community. Bringing together 70+ senior leaders\, academic and technical experts from organisations including Bayer\, Astellas Pharmaceuticals\, REGENXBIO\, AskBio\, Ocugen\, CureDuchenne Ventures and more\, this industry-led forum provides an unrivalled opportunity to share insights\, restore confidence\, and chart a sustainable path forward for gene therapy development. \nDesigned to span the full end-to-end development pipeline\, the summit connects professionals across pre-clinical development\, manufacturing\, analytical development\, clinical operations\, and regulatory affairs. Across 3 days of cutting-edge strategic and technical sessions\, attendees will gain practical learnings on next-generation delivery technologies\, gene editing\, assay development\, and scalable manufacturing strategies\, all with a focus on optimising clinical impact and improving risk–benefit profiles. \nNetworking sits at the heart of the summit experience. With 10+ dedicated networking breaks\, a CEO & Investor Panel\, and carefully curated opportunities to meet peers\, partners\, and decision-makers\, the event is built to foster meaningful\, long-term industry connections. Whether you are looking to exchange technical insights\, explore collaboration opportunities\, or build strategic partnerships\, this is the place to connect with the people shaping the future of gene therapy. \nFeaturing 70+ world-leading speakers\, including C-level executives\, scientific innovators\, and regulatory leaders\, the summit offers a truly comprehensive and collaborative environment for learning\, discussion\, and deal-making. From early-stage development through to clinical and commercial success\, this is your definitive forum to stay ahead in an evolving gene therapy landscape. \nTo learn more about the event\, visit our website here: https://ter.li/b0hfxq
URL:http://www.pharmajournalist.com/event/9th-gene-therapy-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260324
DTEND;VALUE=DATE:20260327
DTSTAMP:20260515T044457
CREATED:20260107T092223Z
LAST-MODIFIED:20260107T092251Z
UID:42661-1774310400-1774569599@www.pharmajournalist.com
SUMMARY:Immune Resetting: B-Cell Mediated & Beyond
DESCRIPTION:Immune Resetting: B-Cell Mediated & Beyond Summit is redefining the conversation around immune modulation and therapeutic innovation. As the global biopharma industry accelerates its focus on autoimmune and inflammatory diseases\, this summit provides an exclusive platform for uncovering the next wave of breakthroughs in B-cell biology and beyond. \nThe event brings together leading immunologists\, clinical researchers\, and pharma executives to explore how precision targeting of B-cell pathways is transforming treatment paradigms. From novel mechanisms of immune resetting to advanced biologics and cell-based strategies\, attendees will gain unparalleled insights into the science driving durable responses and improved patient outcomes. \nConnect with experts from Cabaletta Bio\, GentiBio\, Kite Pharma\, FAU\, Cullian Therapeutics\, Kali Therapeutics\, University of Pittsburgh\, Bristol Myers Squibb\, Oblenio Bio\, and more. \nBeyond the science\, the summit addresses critical challenges in translating these innovations into the clinic\, covering biomarker development\, regulatory considerations\, and scalable manufacturing solutions. With autoimmune disorders and chronic inflammation representing multi-billion-dollar markets\, the discussions will highlight how emerging therapies can meet unmet needs and unlock new commercial opportunities. \nExpect deep dives into cutting-edge research\, candid conversations on investment trends\, and strategic perspectives from industry leaders shaping the next generation of immune-modulating therapies. \nJoin the summit to discover how immune resetting is not just a scientific milestone but a transformative force in global healthcare\, positioning biopharma at the forefront of innovation and patient-centric solutions. \nSee what the current attendees are looking forward to: \n“I look forward to hearing and seeing the latest developments in immune resetting and meeting with a diverse group of researchers in this field. I am also excited to present Hinge’s GEM-DIMER molecule\, HB2198\, for depletion of CD19/CD20 expressing B cells.” \nSenior Director – Preclinical Development\, Hinge Bio  \n“I am interested to share our observations for B-cell depletion and reconstitution in Rese-cel treated individuals and hear what others have seen in their trials.” \nPrincipal Scientist\, Cabaletta Bio 
URL:http://www.pharmajournalist.com/event/immune-resetting-b-cell-mediated-beyond/
LOCATION:AKA Back Bay\, Boston\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260323
DTEND;VALUE=DATE:20260326
DTSTAMP:20260515T044457
CREATED:20260210T171107Z
LAST-MODIFIED:20260210T171107Z
UID:42862-1774224000-1774483199@www.pharmajournalist.com
SUMMARY:11th Innate Killer Summit
DESCRIPTION:The 11th Innate Killer Summit stands at the forefront of innovation in innate immunity\, offering an unparalleled platform for exploring the next generation of NK cell-based therapies and innate immune strategies. As the biopharma industry accelerates its focus on immuno-oncology and cell therapy\, this is the only summit that brings together leading experts and decision-makers to address the scientific\, clinical\, and commercial challenges shaping the dynamic NK field. \nThis year’s faculty includes trailblazers from companies driving NK cell innovation\, such as Artiva Biotherapeutics\, Alloplex Biotherapeutics\, Glycostem\, Indapta Therapeutics\, ImmuneBridge\, and Senti Bio\, alongside academic leaders from institutions like the University of Pennsylvania and MD Anderson Cancer Center. Their insights will illuminate breakthroughs in NK cell engineering\, combination strategies\, and scalable manufacturing solutions that are crucial for advancing these therapies from the bench to the bedside. \nAttendees will gain exclusive access to discussions on optimizing NK cell persistence\, enhancing cytotoxicity\, and overcoming tumor microenvironment challenges. The program also delves into clinical trial progress\, regulatory pathways\, and investment trends\, providing a comprehensive view of how NK cell platforms are transforming cancer treatment and unlocking new therapeutic frontiers. \nThe summit provides a unique opportunity to capture the latest scientific developments\, strategic partnerships\, and commercialization strategies that are redefining the immunotherapy landscape. Expect candid conversations with industry leaders\, data-driven insights\, and forward-looking perspectives on how innate immunity is shaping the future of oncology. \nTo know more visit: https://ter.li/5fn4q8
URL:http://www.pharmajournalist.com/event/11th-innate-killer-summit/
LOCATION:The Westin San Diego Bayview\, 400 W Broadway\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260317
DTEND;VALUE=DATE:20260320
DTSTAMP:20260515T044457
CREATED:20251125T102350Z
LAST-MODIFIED:20251125T102350Z
UID:42483-1773705600-1773964799@www.pharmajournalist.com
SUMMARY:5th Annual Novel Conjugates Summit
DESCRIPTION:Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads and differentiated targeting formats for overcoming drug resistance\, improved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs\, as well as the exploration of non-oncology indications. \nThe 5th Novel Conjugates Summit is the industry’s only dedicated meeting for an insider view into which novel approaches are currently being explored\, what benefit each approach has and the directions the space is heading. \nAttendees gain valuable competitive insight into emerging technologies\, early data\, and the rationale behind each approach\, from established pharma leaders to the newest biotech entrants. Whether your goal is to benchmark your pipeline\, explore partnership opportunities\, or stay ahead of fast-moving design trends\, this summit offers a front-row seat to the next wave of conjugate innovation. \nView the program: https://ter.li/m5sjll
URL:http://www.pharmajournalist.com/event/5th-annual-novel-conjugates-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260309
DTEND;VALUE=DATE:20260311
DTSTAMP:20260515T044457
CREATED:20251016T091056Z
LAST-MODIFIED:20251016T091056Z
UID:42214-1773014400-1773187199@www.pharmajournalist.com
SUMMARY:7th Annual AI in Drug Discovery Conference
DESCRIPTION:The 7th Annual AI in Drug Discovery Conference\, hosted by SAE Media Group\, takes place \n9-10 March 2026 at Hilton London Kensington. This event explores how AI\, machine learning\, and automation are transforming drug discovery – from generative design and molecular modelling to clinical trial optimisation. \nAttendees will hear from Big Pharma and Biotech senior leaders including Novartis\, GSK\, AstraZeneca\, Sanofi\, and more\, with sessions covering LLMs\, autonomous agents\, and MLOps. With sponsors like Schrödinger\, the conference delivers cutting-edge insights\, high-level networking\, and practical strategies to accelerate innovation. \nBook now
URL:http://www.pharmajournalist.com/event/7th-annual-ai-in-drug-discovery-conference/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:alessandra.demaria@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260226
DTEND;VALUE=DATE:20260228
DTSTAMP:20260515T044457
CREATED:20251009T103636Z
LAST-MODIFIED:20251009T103636Z
UID:42156-1772064000-1772236799@www.pharmajournalist.com
SUMMARY:Targeted Therapies Partnering & Licensing Summit Asia
DESCRIPTION:Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster\, & Biotech Access to International Partnerships & Capital \nWith fast\, cost-effective clinical infrastructure\, generous government incentives\, and simplified regulatory pathways\, Asia’s biotech ecosystem has emerged as a global launchpad for innovation. Western pharma and biotech companies are increasingly turning to de-risked assets from Asia to supercharge their clinical pipelines and gain a competitive edge. \nFor NewCo\, private and public biotech or small pharma\, this accessible forum offers: \n\nHigh seniority and quality of attendees across pharma and other biotech\nTargeted focus\, purpose-built format\, and One-on-One Partnering™ portal allowing you to make meaningful connections easier and more efficient\nInformative presentations and discussions nuanced to considerations for deal-making across targeted therapies\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/targeted-therapies-partnering-licensing-summit-asia/
LOCATION:The Westin Tokyo\, 1-4-1 Mita Meguro-ku\, Tokyo\, Tokyo 153-8580\, Japan
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260224
DTEND;VALUE=DATE:20260227
DTSTAMP:20260515T044457
CREATED:20251204T131433Z
LAST-MODIFIED:20251204T131433Z
UID:42559-1771891200-1772150399@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences Europe 2026
DESCRIPTION:Now in its 8th year\, LEAP HR: Life Sciences Europe is where the industry’s most ambitious HR leaders come together to find new solutions to their most pressing people challenges that they can immediately deploy to demonstrate meaningful business impact. Uncover the boldest strategies for driving talent agility\, embedding AI and analytics\, and building future-ready workforces – proven to cut costs\, boost engagement\, and accelerate growth. \nThis is the only forum dedicated to the unique and specific HR\, L&D\, and TA opportunities and challenges faced by life science organisations of all sizes across Europe. Join us next February to collaborate with like-minded HR leaders and uncover how to attract\, develop\, and retain top talent in a rapidly changing landscape. \nOver three jam-packed days\, gain actionable takeaways with proven ROI through case studies\, structured networking\, dedicated panels\, roundtable discussions\, and speed learning sessions. Topics range from employment engagement in uncertain marketers to AI-driven HR innovation\, creative compensation design\, and more. \nYou’ll connect with peers who are reimagining HR’s role as driver of strategic value and organizational impact\, sharing real-world case studies\, practical solutions\, with the ROI behind every leap. \nTo learn more and download the agenda\, please click here.
URL:http://www.pharmajournalist.com/event/leap-hr-life-sciences-europe-2026/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260224
DTEND;VALUE=DATE:20260227
DTSTAMP:20260515T044457
CREATED:20251204T130129Z
LAST-MODIFIED:20251204T130911Z
UID:42543-1771891200-1772150399@www.pharmajournalist.com
SUMMARY:3rd IMPACCT Real World Evidence Summit Europe
DESCRIPTION:As regulators and payers increasingly elevate the importance of RWE in submission and reimbursement requirements\, the upcoming EHDS regulation marks a landmark move towards data sharing\, and increasingly robust AI transforms big data analysis\, it has never been more critical to harness RWE to uncover unmet needs\, demonstrate treatment value beyond the clinical trial setting\, and influence decision-making across regulators\, payers\, providers\, and patients. \nThe 3rd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE\, Evidence Generation\, and Medical Affairs to consolidate\, innovate and apply RWE across the drug development lifecycle\, from external control arms to reimbursement. \nWith a tight focus on leveraging AI for big data analysis\, accessing standardised and high-quality datasets\, and creating a robust integrated evidence strategy\, join 60+ industry pioneers from AstraZeneca\, Pfizer\, Novartis\, Boehringer Ingelheim and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice. \nTo learn more and download the agenda\, please click here.
URL:http://www.pharmajournalist.com/event/3rd-impacct-real-world-evidence-summit-europe/
LOCATION:Radisson Blu Hotel\, Rusland 17\, Amsterdam\, 1012 CK\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260224
DTEND;VALUE=DATE:20260227
DTSTAMP:20260515T044457
CREATED:20251121T123049Z
LAST-MODIFIED:20251121T123049Z
UID:42464-1771891200-1772150399@www.pharmajournalist.com
SUMMARY:Measuring Impact in Medical Affairs Summit
DESCRIPTION:The Measuring Impact in Medical Affairs Summit is uniting Medical Affairs leaders from across pharma and biotech to define\, benchmark\, and standardize meaningful KPIs that capture the true value of Medical Affairs activities. \nAs Medical Affairs cements its role as the strategic bridge between R&D and commercialization\, the pressure to quantify and communicate impact has never been greater. In an era of tighter budgets\, digital transformation\, and AI-driven analytics\, teams must move beyond activity tracking to demonstrate measurable outcomes that drive scientific\, stakeholder\, and commercial success. \nThis year\, join 50+ experts from Boehringer Ingelheim\, Abbvie\, Alexion\, Travere\, Regeneron\, and more to explore how leading teams are designing metrics that reflect quality over quantity\, leveraging AI to enhance insight generation\, and co-creating the next generation of KPIs defining Medical Affairs excellence. Don’t miss the only meeting dedicated to transforming Medical Affairs from an activity-based to an impact-driven function. \nFind out more: https://ter.li/ymwe2l
URL:http://www.pharmajournalist.com/event/measuring-impact-in-medical-affairs-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260223
DTEND;VALUE=DATE:20260225
DTSTAMP:20260515T044457
CREATED:20260106T121653Z
LAST-MODIFIED:20260106T121736Z
UID:42640-1771804800-1771977599@www.pharmajournalist.com
SUMMARY:SmartLab Exchange Europe
DESCRIPTION:Across pharma\, biotech\, chemicals\, FMCG\, and beyond\, laboratory leaders are facing the same challenge: how to turn the vision of a smart\, digital lab into reality. From harmonising data and making it AI-ready to unlocking the true value of automation\, the journey from concept to execution is complex – but critical. \nSmartLab Exchange Europe 2026 is where innovation meets implementation. This exclusive\, invitation-only event brings together senior laboratory\, R&D\, and digital transformation leaders to focus on practical strategies that make digitalisation work in practice. Over two days in Amsterdam\, you’ll explore how to overcome data silos\, scale automation\, and drive adoption – from the bench to the boardroom. \nThrough curated roundtables\, one-to-one meetings\, and real-world case studies\, you’ll gain actionable insights on: \n\nHow to efficiently sort your lab data so that it becomes ‘FAIR’\nPractical steps to make sure data is AI-ready\nCase studies from those already implementing AI and Automation to prove the value that can be unlocked\nHow to overcome resistance and drive change across teams and systems\n\nWho Should Attend?\nSenior professionals in R&D\, QA/QC\, IT\, and digital transformation roles from pharma\, biotech\, chemicals\, FMCG\, and food & beverage organisations. \nLearn More:\nView the event guide to explore the full agenda\, speaker lineup\, and venue details to see why the SmartLab Exchange Europe is the must-attend event for laboratory leaders. \nSpaces are strictly limited. Secure your invitation today and join us in Amsterdam for two days of strategic collaboration and innovation.
URL:http://www.pharmajournalist.com/event/smartlab-exchange-europe-2026/
LOCATION:Leonardo Royal Hotel Amsterdam\, Netherlands
ORGANIZER;CN="IQPC Exchange":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260223
DTEND;VALUE=DATE:20260227
DTSTAMP:20260515T044457
CREATED:20251021T104830Z
LAST-MODIFIED:20251021T104830Z
UID:42225-1771804800-1772150399@www.pharmajournalist.com
SUMMARY:16th World ADC London
DESCRIPTION:The Longest Standing & Pre-Eminent European ADC Forum\n16th World ADC London | 800+ Industry Attendees | 240+ Companies | 110+ Global Speakers \nWith traditional ADCs now fulfilling their potential to reshape oncology care\, the bioconjugate community is doubling down on differentiation to ensure the next generation delivers meaningful patient impact. \nReturning as the longest-standing and definitive ADC forum in Europe\, 16th World ADC London 2026 is the must-attend event for anyone working in or looking to learn about bioconjugates. Leverage cutting-edge R&D\, strategic insights\, and unparalleled networking to advance ADC innovation and maximise therapeutic potential. \nAgenda Highlights:\nThe 2026 programme features 5 end-to-end content streams covering discovery\, preclinical translation\, clinical lessons\, process & analytical development\, and manufacturing & supply chain. Sessions are infused with trailblazing approaches to overcome patient resistance and accelerate ADCs into earlier-line oncology treatments. Topics include: \n\nNovel cytotoxic and non-cytotoxic payloads\nDual payload ADCs\nBispecific and biparatopic ADCs\nNon-antibody and fragment conjugates\n\nGlobal Speaker Faculty:\nHear from 110+ experts across Europe\, North America\, and Asia sharing actionable insights to advance your pipeline\, including: \n\nElaine Hurt\, Executive Director & Head\, Tumour Targeted Delivery Bioscience\, Oncology R&D\, AstraZeneca\nGuillaume Bergthold\, Executive Director\, Clinical Development\, Daiichi Sankyo\nAlan Russell\, VP Research & Head\, R&D Technology & Innovation\, Amgen\nAndras Strassz\, Chief Medical Officer\, Heidelberg Pharma\nMarija Vrljic\, VP\, Antibody Technologies\, ALX Oncology (New Company)\nJonathan Davis\, Director\, ADC Discovery\, Helix Biopharma (New Company)\nZhenwei Miao\, Founder & Chairman\, Adcoris Biopharma (New Company)\n\nWho Will Attend:\nJoin 800+ senior ADC decision-makers from biopharma\, clinical research\, service providers\, investors\, and regulators\, uniting to shape the future of ADC development. \nExplore the full agenda for a complete breakdown of all sessions\, speakers\, and networking opportunities.
URL:http://www.pharmajournalist.com/event/16th-world-adc-london/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260203
DTEND;VALUE=DATE:20260206
DTSTAMP:20260515T044457
CREATED:20251111T143537Z
LAST-MODIFIED:20251111T143537Z
UID:42367-1770076800-1770335999@www.pharmajournalist.com
SUMMARY:2nd Proteomics-Based Drug Discovery Summit
DESCRIPTION:With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates\, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone\, the increasing recognition of proteomics as a transformative force in drug discovery is unquestionable. \nReturning to Boston for its second year\, the Proteomics-Based Drug Discovery Summit is the premier industry event dedicated to harnessing the full power of proteomics across drug discovery pipelines. Designed for scientific innovators like you\, explore how next-generation proteomic platforms are accelerating understanding of pathology\, unveiling novel drug targets\, and transforming hit-to-lead development. \nWith a special focus on optimizing proteomics instruments to balance throughput and sensitivity\, automating sample processing\, unveiling hidden disease mechanisms with PTM analysis\, and defining gold-standard analysis methodologies; this forum is ideal for proteomics leaders aiming to expand the druggable proteome and achieve therapeutic options for diseases with unmet need. \nAs proteomics continues to evolve\, make headlines\, and revolutionize therapeutic development\, unite with 70+ Directors\, Vice Presidents and Experts in Proteomics\, Chemical Biology\, Mass Spectrometry and Bioinformatics to achieve protein level insights to advance your own discovery pipeline. \nTo know more visit: https://ter.li/t6xjio
URL:http://www.pharmajournalist.com/event/2nd-proteomics-based-drug-discovery-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260203
DTEND;VALUE=DATE:20260206
DTSTAMP:20260515T044457
CREATED:20251111T142214Z
LAST-MODIFIED:20251111T142214Z
UID:42355-1770076800-1770335999@www.pharmajournalist.com
SUMMARY:10th Liquid Biopsy for Precision Oncology Summit
DESCRIPTION:The past decade has transformed liquid biopsy\, which was previously just an exciting concept\, into a routine\, commercially viable technology that is saving patients’ lives and transforming clinical trials. \nUniting the field in San Diego February 3-5\, 2026 for 3 days of data- and strategy-driven presentations and networking sessions\, the 10th Liquid Biopsy for Precision Oncology Summit returns to deliver unparalleled insights\, data\, technology updates\, and strategies spanning the entire drug development pipeline – from preclinical discovery\, through clinical translation\, to regulatory approval\, reimbursement\, and commercial adoption. \nIf you are working in precision oncology\, or need enhanced insights into your patient population\, optimized diagnostic and prognostic tools\, or earlier detection of disease\, this meeting should be considered a staple entry in your conference calendar. Across ctDNA\, MRD\, multi-omic biomarkers\, and novel analytes\, you will see how pharma are strategically integrating liquid biopsies into therapeutic pipelines\, how diagnostic companies are designing more sensitive assays\, and how the field is overcoming barriers to widespread clinical adoption. \n\nSee the full event guide here: https://ter.li/nwkakw\nWith free* tickets available for biopharma\, visit the website to register: https://ter.li/2ewl2u\n\n*Subject to terms and conditions
URL:http://www.pharmajournalist.com/event/10th-liquid-biopsy-for-precision-oncology-summit/
LOCATION:San Diego Marriot La Jolla\, 4240 La Jolla Village Dr\, La Jolla\, CA\, 92037\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260203
DTEND;VALUE=DATE:20260206
DTSTAMP:20260515T044457
CREATED:20250919T104339Z
LAST-MODIFIED:20250919T104709Z
UID:41969-1770076800-1770335999@www.pharmajournalist.com
SUMMARY:14th Alzheimer's & Parkinson's Drug Development Summit
DESCRIPTION:Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as α-synuclein\, neuroinflammation\, and metabolic targets. Against the backdrop of a globally surging patient population\, the urgency for more effective\, disease-modifying interventions has never been greater. \nIn its 14th year\, the Alzheimer’s and Parkinson’s Drug Development Summit is committed to spotlighting the latest trailblazing innovation\, from novel interventions for disease modification\, encompassing protein aggregation\, neuroinflammation\, metabolic pathways\, neurotrophic factors and more to the groundbreaking progress in p-tau217 and fluid-based biomarkers. \nThe 2026 program is built to explore disease progression\, modification and prodromal intervention\, so the next generation of therapeutics can prevent as well provide a meaningful impact to neurodegenerative patients in need. \nWhat can you expect? \n\n2 deep dive workshops into in vivo and in vitro modelling advancements\nSeminar day on fluid-based biomarker innovation\n30+ expert speakers including industry leaders\, academic KOLs and patient voices\nMultiple tracks of content spanning discovery\, preclinical\, clinical and regulatory\n10+ hours dedicated networking time over 3 days\n\nDon’t miss your opportunity to connect with leading drug developers and discover next-generation therapeutics redefining neurodegenerative treatment. \nFind out more here – https://ter.li/ybtrdq
URL:http://www.pharmajournalist.com/event/14th-alzheimers-parkinsons-drug-development-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260128
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T044457
CREATED:20251119T141849Z
LAST-MODIFIED:20251204T124644Z
UID:42408-1769558400-1769731199@www.pharmajournalist.com
SUMMARY:10th Tumor Models Summit San Francisco
DESCRIPTION:Join the West Coast’s premier pharma and biotech gathering\, the 10th Tumor Models Summit San Francisco\, where innovation meets opportunity in tumor modeling. \nAs the FDA phases out animal testing requirements and NIH redirects funding away from animal-only studies\, the oncology landscape is transforming. Exciting modalities like ADCs\, bispecifics\, T-cell engagers demand smarter\, more predictive models. CRISPR and AI are accelerating patient-derived model development at unprecedented speed. \nThis meeting unites industry leaders with cutting-edge vendors to navigate this pivotal shift. Network with pioneers shaping the future of optimizing model selection strategy\, discover breakthrough technologies\, and position your pipeline ahead of the curve. The industry is evolving; the time is now to be part of the conversation. \nDownload the full event guide to find out more: https://ter.li/phkowi
URL:http://www.pharmajournalist.com/event/10th-tumor-models-summit-san-francisco/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point St\, San Francisco\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T044457
CREATED:20251204T125152Z
LAST-MODIFIED:20251204T125420Z
UID:42534-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:6th Age-Related Disease Therapeutics Summit
DESCRIPTION:The 6th Age-Related Disease Therapeutics Summit is the leading global meeting dedicated to advancing therapies that target the biology of aging and age-related diseases. \nOver three days\, the summit brings together senior decision-makers from biopharma\, biotech innovators\, investors\, and academic researchers to accelerate the development and commercialization of next-generation therapeutics. \nAs the aging population grows\, the demand for interventions that extend healthspan and treat chronic conditions is at an all-time high. This meeting provides a unique platform for professionals to explore cutting-edge science\, clinical progress\, and translational strategies shaping this rapidly evolving field. \nFrom senolytics and cellular rejuvenation to mitochondrial health and systemic inflammation\, the summit covers the most promising approaches in age-related disease treatment. \nKey highlights include: \n\nDeep-dive sessions on therapeutic targets\, biomarker validation\, and regulatory pathways.\nInvestment & Funding Insights: Hear from leading investors and strategists on where capital is flowing in longevity and age-related disease innovation.\nNetworking Opportunities: Connect with C-suite executives\, R&D leaders\, and pioneering scientists driving breakthroughs in aging biology.\n\nHere are just some of the ground-breaking companies that will be presenting this year: \nAge 1 | BioAge Labs | Biolexis Therapeutics | Gordian Biotechnology | Insilico Medicine | Juvenescence | Kendall Capital Partners | Novartis | Rubedo Life Sciences | Telocyte \nFind out more\, here: https://ter.li/b3tokv
URL:http://www.pharmajournalist.com/event/6th-age-related-disease-therapeutics-summit-2026/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point Street\, San Francsico\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260127
DTEND;VALUE=DATE:20260130
DTSTAMP:20260515T044457
CREATED:20251111T143842Z
LAST-MODIFIED:20251111T143842Z
UID:42373-1769472000-1769731199@www.pharmajournalist.com
SUMMARY:5th mRNA-Based Therapeutics Summit Europe
DESCRIPTION:The 5th mRNA-Based Therapeutics Summit Europe is the leading European industry-focused forum dedicated to accelerating the safe\, scalable\, and clinically impactful development of messenger RNA (mRNA) medicines. Returning for its fifth year in Berlin from 27 – 29 January 2026\, this essential meeting unites 170+ senior leaders across R&D\, CMC (Chemistry\, Manufacturing\, and Controls)\, Regulatory Affairs\, Clinical Development\, and Business Strategy from Europe and around the globe. \nThe summit provides a comprehensive\, end-to-end program\, featuring never-before-seen preclinical and clinical data from industry trailblazers such as Moderna\, AstraZeneca\, and BioNTech. The agenda is meticulously structured to address the field’s most pressing challenges and opportunities: broadening mRNA’s scope beyond infectious disease vaccines into oncology\, rare diseases\, and beyond; overcoming the key bottleneck of targeted and tissue-specific delivery; and resolving complex CMC and stability hurdles for next-generation modalities like self-amplifying RNA (saRNA) and circular RNA (circRNA). \nNew for 2026 is a dedicated Gene Editing Focus Day\, highlighting how mRNA technology enables safer\, transient editing strategies and exploring its translational potential in regenerative indications. Attendees will gain actionable\, exclusive insights on critical topics including advanced LNP and polymeric delivery systems\, manufacturing scale-up\, and the integration of AI into mRNA design. \nAdditionally\, the summit offers high-profile investor sessions\, providing candid perspectives on the clinical milestones\, strategic proof points\, and investment signals necessary to make an mRNA platform fundable in today’s competitive landscape. By fostering collaboration and sharing best practices\, the 5th mRNA-Based Therapeutics Summit Europe is the premier platform to de-risk development pipelines and ensure the next generation of revolutionary mRNA medicines successfully reach patients. \nTo know more visit: https://ter.li/t3lsz2
URL:http://www.pharmajournalist.com/event/5th-mrna-based-therapeutics-summit-europe/
LOCATION:Hotel Palace Berlin\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR